Rational drug combination design in patient-derived avatars reveals effective inhibition of hepatocellular carcinoma with proteasome and CDK inhibitors.

Lim, Jhin Jieh; Hooi, Lissa; Dan, Yock Young; Bonney, Glenn K; Zhou, Lei; Chow, Pierce K-H; Chee, Cheng Ean; Toh, Tan Boon; Chow, Edward K-H

Lim, Jhin Jieh; Hooi, Lissa; Dan, Yock Young; Bonney, Glenn K; Zhou, Lei; Chow, Pierce K-H; Chee, Cheng Ean; Toh, Tan Boon; Chow, Edward K-H.

Afiliación

Lim JJ; Cancer Science Institute of Singapore, National University of Singapore, 14 Medical Drive, 117599, Singapore, Singapore.
Hooi L; NUS Centre for Cancer Research (N2CR), Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.
Dan YY; Cancer Science Institute of Singapore, National University of Singapore, 14 Medical Drive, 117599, Singapore, Singapore.
Bonney GK; NUS Centre for Cancer Research (N2CR), Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.
Zhou L; Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.
Chow PK; Division of Hepatobiliary and Liver Transplantation Surgery, National University Health System, Singapore, Singapore.
Chee CE; Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.
Toh TB; Department of Hepatopancreatobiliary and Transplant Surgery, Singapore General Hospital, Singapore, Singapore.
Chow EK; Department of Haematology-Oncology, National University Cancer Institute, Singapore, Singapore.

J Exp Clin Cancer Res ; 41(1): 249, 2022 Aug 15.

Article en En | MEDLINE | ID: mdl-35971164

Asunto(s)

Antineoplásicos; Carcinoma Hepatocelular; Neoplasias Hepáticas; Animales; Antineoplásicos/farmacología; Bortezomib/farmacología; Bortezomib/uso terapéutico; Carcinoma Hepatocelular/tratamiento farmacológico; Carcinoma Hepatocelular/patología; Línea Celular Tumoral; Combinación de Medicamentos; Humanos; Neoplasias Hepáticas/tratamiento farmacológico; Neoplasias Hepáticas/patología; Ratones; Complejo de la Endopetidasa Proteasomal; Inhibidores de Proteasoma/farmacología; Inhibidores de Proteínas Quinasas/farmacología; Inhibidores de Proteínas Quinasas/uso terapéutico; Sorafenib/uso terapéutico; Ensayos Antitumor por Modelo de Xenoinjerto

Palabras clave

CDK inhibitors; Combination therapy; Hepatocellular carcinoma; Organoids; Patient-derived xenograft; Proteasome inhibitors

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Carcinoma Hepatocelular / Neoplasias Hepáticas / Antineoplásicos Idioma: En Revista: J Exp Clin Cancer Res Año: 2022 Tipo del documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google